Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

K. Wenn; L. Tomala; S. Wilop; L. Vankann; C. Hasenbank; O. Frank; A. Hochhaus; F. J. Giles; T. Lange; M. C. Müller; S. Koschmieder; F. Beier; P. Ziegler; T. H. Brümmendorf

doi:10.1038/leu.2015.245

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

K. Wenn
, L. Tomala
, S. Wilop
, L. Vankann
, C. Hasenbank
, O. Frank
, A. Hochhaus
, F. J. Giles
, T. Lange
, M. C. Müller
, S. Koschmieder
, F. Beier
, P. Ziegler
, T. H. Brümmendorf

Research output: Contribution to a Journal (Peer & Non Peer) › Letter › peer-review

21 Citations (Scopus)

Original language	English
Pages (from-to)	2402-2404
Number of pages	3
Journal	Leukemia
Volume	29
Issue number	12
DOIs	https://doi.org/10.1038/leu.2015.245
Publication status	Published - 1 Dec 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/leu.2015.245

Cite this

Wenn, K., Tomala, L., Wilop, S., Vankann, L., Hasenbank, C., Frank, O., Hochhaus, A., Giles, F. J., Lange, T., Müller, M. C., Koschmieder, S., Beier, F., Ziegler, P., & Brümmendorf, T. H. (2015). Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. Leukemia, 29(12), 2402-2404. https://doi.org/10.1038/leu.2015.245

@article{e8f826334f044ba5bb9499d30349b2dd,

title = "Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib",

author = "K. Wenn and L. Tomala and S. Wilop and L. Vankann and C. Hasenbank and O. Frank and A. Hochhaus and Giles, \{F. J.\} and T. Lange and M{\"u}ller, \{M. C.\} and S. Koschmieder and F. Beier and P. Ziegler and Br{\"u}mmendorf, \{T. H.\}",

year = "2015",

month = dec,

day = "1",

doi = "10.1038/leu.2015.245",

language = "English",

volume = "29",

pages = "2402--2404",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "12",

}

Wenn, K, Tomala, L, Wilop, S, Vankann, L, Hasenbank, C, Frank, O, Hochhaus, A, Giles, FJ, Lange, T, Müller, MC, Koschmieder, S, Beier, F, Ziegler, P & Brümmendorf, TH 2015, 'Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib', Leukemia, vol. 29, no. 12, pp. 2402-2404. https://doi.org/10.1038/leu.2015.245

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. / Wenn, K.; Tomala, L.; Wilop, S. et al.
In: Leukemia, Vol. 29, No. 12, 01.12.2015, p. 2402-2404.

Research output: Contribution to a Journal (Peer & Non Peer) › Letter › peer-review

TY - JOUR

T1 - Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

AU - Wenn, K.

AU - Tomala, L.

AU - Wilop, S.

AU - Vankann, L.

AU - Hasenbank, C.

AU - Frank, O.

AU - Hochhaus, A.

AU - Giles, F. J.

AU - Lange, T.

AU - Müller, M. C.

AU - Koschmieder, S.

AU - Beier, F.

AU - Ziegler, P.

AU - Brümmendorf, T. H.

PY - 2015/12/1

Y1 - 2015/12/1

UR - https://www.scopus.com/pages/publications/84951569512

U2 - 10.1038/leu.2015.245

DO - 10.1038/leu.2015.245

M3 - Letter

C2 - 26369986

AN - SCOPUS:84951569512

SN - 0887-6924

VL - 29

SP - 2402

EP - 2404

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

UN SDGs

Access to Document

Other files and links

Cite this